To include your compound in the COVID-19 Resource Center, submit it here.

Ligand approach to IGF

MedImmune MEDI-573 targets ligands in IGF pathway, where many cancer drugs fail

While drug companies have been targeting insulin-like growth factor-1 receptor since it was first implicated in cancer almost two decades ago, the strategy has yet to bear fruit because of tumor resistance and off-target effects. AstraZeneca plc's MedImmune LLC subsidiary thinks it can avoid those issues by targeting the receptor's ligands IGF-1 and IGF-2 with its MEDI-573 antibody.

Jerry McMahon, SVP of R&D and head of the oncology innovative medicines unit at MedImmune, said preclinical

Read the full 743 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE